Earnings Per Share (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Reconciliation of Numerator and Denominator of Basic and Diluted Earnings per Share

A reconciliation of the numerator and denominator of basic and diluted earnings per share follows (dollars in millions, except per share amounts; shares in thousands):


	Year Ended December 31,
	2023		2022		2021

Numerator:
Net loss attributable to Surgery Partners, Inc.	$	(11.9)	$	(54.6)	$	(70.9)
Less: Amounts allocated to participating securities (1)	—		—		(10.3)
Net loss attributable to common stockholders	$	(11.9)	$	(54.6)	$	(81.2)

Denominator:
Weighted average common shares outstanding:
Basic	125,613		91,952		72,427
Diluted (2)	125,613		91,952		72,427

Net loss per share attributable to common stockholders:
Basic	$	(0.09)	$	(0.59)	$	(1.12)
Diluted (2)	$	(0.09)	$	(0.59)	$	(1.12)

Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive:
Stock options	1,246		1,459		1,920
Restricted shares	263		679		1,452

(1)Includes dividends accrued for the Series A Preferred Stock. The Series A Preferred Stock does not participate in undistributed losses and was converted to common stock during the second quarter of 2021. There were no participating securities for the years ended December 31, 2023 and 2022.

(2)The impact of potentially dilutive securities for all periods were not considered because the effect would be anti-dilutive.